Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961313 | 0.83 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A9EPHX2GRIN1 | |
| SCHEMBL1677044 | 0.83 | SLC6A4 (0.48) | SLC6A4SLC6A3SLC6A9GRIN1GRIN2A | |
| SCHEMBL22817125 | 0.77 | SLC6A4 (0.65) | SLC6A4SLC6A3HSD11B1EPHX2LIPE | |
| SCHEMBL8350802 | 0.76 | KMT2A (0.41) | SLC6A4SLC6A3SLC6A9HSD11B1GRIN1 | |
| SCHEMBL19613327 | 0.76 | SIGMAR1 (0.55) | SLC6A4SLC6A3SLC6A9GRIN1GRIN2A | |
| SCHEMBL22816521 | 0.76 | SLC6A4 (0.63) | SLC6A4SLC6A3HSD11B1EPHX2LIPE | |
| SCHEMBL3516539 | 0.75 | SLC6A4 (1.00) | SLC6A4SLC6A3HSD11B1SLC6A2 | |
| SCHEMBL1244796 | 0.75 | FFAR4 (0.50) | SLC6A4SLC6A3LIPE | |
| SCHEMBL1677083 | 0.75 | SLC6A9 (0.46) | SLC6A4SLC6A3SLC6A9 | |
| SCHEMBL1677030 | 0.73 | EPHX2 (0.53) | EPHX2LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-2346820-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| WO-2009151152-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | SLC6A4 838/4885SLC6A3 990/4885SLC6A9 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.